Portage Biotech (NASDAQ:ATON) Stock Price Up 3.8% – Here’s What Happened

Portage Biotech Inc. (NASDAQ:ATON) traded up 3.8% during trading on Thursday . The stock traded as high as $0.3504 and last traded at $0.3320. 9,777,470 shares traded hands during trading, an increase of 209% from the average session volume of 3,165,393 shares. The stock had previously closed at $0.32.

Analyst Ratings Changes

Separately, HC Wainwright began coverage on shares of Portage Biotech in a research report on Tuesday, February 24th. They set a “buy” rating and a $2.00 target price for the company. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $2.00.

Portage Biotech Price Performance

The firm’s fifty day moving average price is $0.33. The stock has a market capitalization of $7.78 million, a price-to-earnings ratio of -0.04 and a beta of 0.49.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.